These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8522478)

  • 1. BO-2727, meropenem and imipenem disc diffusion susceptibility testing criteria.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1995 Aug; 36(2):444-6. PubMed ID: 8522478
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2001 Jul; 48(1):23-8. PubMed ID: 11418509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
    Queenan AM; Shang W; Flamm R; Bush K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):565-9. PubMed ID: 19884379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
    Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
    J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
    Baek JY; Ko KS; Kang CI; Song JH; Peck KR
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):297-300. PubMed ID: 21855246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
    Gimeno C; Cantón R; García A; Gobernado M;
    Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility testing of Stenotrophomonas maltophilia to carbapenems.
    Howe RA; Wilson MP; Walsh TR; Millar MR
    J Antimicrob Chemother; 1997 Jul; 40(1):13-7. PubMed ID: 9249199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of carbapenem testing: the COMPACT study.
    Nordmann P; Picazo JJ; Mutters R; Korten V; Quintana A; Laeuffer JM; Seak JC; Flamm RK; Morrissey I;
    J Antimicrob Chemother; 2011 May; 66(5):1070-8. PubMed ID: 21393160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.
    Nakagawa S; Hashizume T; Matsuda K; Sanada M; Okamoto O; Fukatsu H; Tanaka N
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2756-9. PubMed ID: 8109950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
    Powell M; Seetulsingh P; Williams JD
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():175-81. PubMed ID: 2808206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE; Lindmark A; Persson I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The postantibiotic effect of meropenem and imipenem on selected bacteria.
    Nadler HL; Pitkin DH; Sheikh W
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():225-31. PubMed ID: 2509416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp.
    Yazawa K; Mikami Y; Ohashi S; Miyaji M; Ichihara Y; Nishimura C
    J Antimicrob Chemother; 1992 Feb; 29(2):169-72. PubMed ID: 1506332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.